Navigation Links
Pharmalink AB Raises SEK 35 Million Through Share Issue
Date:1/4/2012

STOCKHOLM, January 4, 2012 /PRNewswire/ --

Pharmalink AB, today announces it has raised SEK 35 million through a rights issue of new shares to the Company's existing shareholders, including Industrifonden.

The new funds will be used to further advance Nefecon® and Busulipo™, Pharmalink's two lead product candidates. Nefecon is the first pharmaceutical product especially developed for patients with IgA nephropathy, the most common form of primary glomerulonephritis and a cause of end-stage renal disease requiring treatment with dialysis or transplantation. Nefecon has shown positive results in an open-labeled Phase II trial evaluating safety and efficacy and Pharmalink is currently focusing on preparing pivotal clinical trials.

Busulipo is being developed to provide a best-in-class conditioning agent for use priorto hematopoietic stem cell transplantation (HSCT), also often known as bone marrow transplantation. Busulipo has successfully undergone Phase II clinical trials and extensive data on efficacy, safety and pharmacokinetics compare positively with historical controls. Pharmalink is currently preparing for late stage clinical trials and for the registration and introduction of Busulipo into key global markets.

Pharmalink's Managing Director Johan Häggblad said, "Pharmalink's ability to raise capital in the current difficult economic climate reflects the potential of our product pipeline and the confidence our shareholders have in our Company and strategy. Our two main product candidates have shown very promising results and this new funding will support their further progress towards becoming new medicines for important indications."

Lennart Hansson, Investment Director at Industrifonden and member of the Pharmalink Board said: "As part of Industrifonden's investment strategy, we are seeking to direct more significant capital to work in those companies we believe will deliver major successes. Pharmalink is very much in that category. The Company has shown the quality of its drug development capabilities through successful outlicensing and, in Busulipo and Nefecon, has product candidates with the potential to generate great value for investors. We very much look forward to Pharmalink continuing its work in turning these Swedish medical innovations into products that can make a real difference to patients."

About Pharmalink

Pharmalink is a Swedish specialty pharma company developing high value products for niche indications. Pharmalink draws on its extensive experience of pharmaceutical product development and the excellence of medical science in Sweden to identify and progress products that address significant unmet medical needs. Pharmalink has introduced more than 15 pharmaceutical products to the market. Using a repurposing and reformulation strategy, Pharmalink minimizes the risk of product development. The Company's strategy is to apply its expertise to drive drug development and commercialize with partners. Pharmalink currently has two clinical phase projects under development, Nefecon® and Busulipo™, and is actively in-licensing promising new projects to add to its pipeline. Visit http://www.pharmalink.se for further information.

For further information, please contact:

Pharmalink AB:
Johan Häggblad, Managing Director, +46(0)70-668-0644
Email: johan.haggblad@pharmalink.se
http://www.pharmalink.se

Citigate Dewe Rogerson:
Chris Gardner/Nina Enegren, +44-207-638-9571



'/>"/>
SOURCE Pharmalink
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmalink AB Receives US Orphan Drug Designation for Nefecon(R) (PL-56)
2. Grifols Agrees to Acquire Intellectual Property for Treatment of Post-Polio Syndrome From Pharmalink AB
3. Pharmalink AB Receives Patent for Nefecon(R) Principle
4. MacuCLEAR, Inc. Raises More Than $1M in Financing and Enters into Strategic Pacific Rim Partnership
5. Cohera Medical Raises Over $25 Million in Series C Round
6. ImmusanT Raises $20 Million in Series A Financing to Advance Immunotherapeutic and Diagnostic for Celiac Disease
7. arGEN-X raises EUR 27.5 million (USD 37 million) in oversubscribed Series B Round
8. Vista Partners Updates Coverage on Cellmid Limited; Raises Target Price to AUD $0.12
9. Bayer Virtual Walk for Hemophilia Raises Awareness and Funds for People With Bleeding Disorders
10. NxStage Reports Record Third Quarter 2011 Financial Results and Raises Revenue Guidance For 2011
11. FRC Praises House Committee for Holding Hearing on Conscience-Violating Obamacare Contraceptive Mandate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... you know that PhRMA member companies invested $65.5 billion in research ... medicines, generics and the supply chain account for 14 percent of ... this (7 percent)? Or that the United States ... in high-growth biopharmaceutical startups? ... The biopharmaceutical industry accounts for ...
(Date:7/17/2017)... , July 17, 2017  MedX Holdings, Inc., ... medical testing, strengthening and rehabilitation equipment, today announced the ... Program. MedX is considered the gold standard for the ... in specialized medical strengthening equipment. ... lease with the physician or practice who prescribe the ...
(Date:7/14/2017)... LAS VEGAS , July 13, 2017 It ... the United States is in the midst of ... Disease Control , since 1999, the number of overdose deaths ... , "resulting in over half a million dead from 2001 ... like codeine, oxycodone, and hydrocodone has similarly quadrupled, drawing a ...
Breaking Medicine Technology:
(Date:7/27/2017)... ... July 27, 2017 , ... MAP Health Management, LLC., ... Fierce Innovation Awards: Healthcare Edition 2017, an awards program from the publisher of ... Health Management/Patient Engagement Solutions. , MAP was selected as a finalist for ...
(Date:7/27/2017)... ... July 27, 2017 , ... Team Novo Nordisk, the world’s first all-diabetes ... pro squad as a stagiaire for the remainder of the 2017 season. One of ... 31st at the Tour of Utah. , “Every season we are excited to move ...
(Date:7/27/2017)... York, NY (PRWEB) , ... July 27, 2017 ... ... to President Barack Obama from 2012-2016, will keynote Day 2 of the HIMSS ... The event kicks off at the Sheraton Boston Hotel, Sept. 11-13, 2017. , ...
(Date:7/26/2017)... , ... July 26, 2017 , ... Capillus, LLC has ... hereditary hair loss. The new Flexible Fitting Design offers a more comfortable, adaptable fit ... is delighted with the improvements to the home-use laser therapy caps intended to improve ...
(Date:7/26/2017)... (PRWEB) , ... July 26, 2017 , ... Six greater Bay Area roller derby leagues ... “Make ‘em Bleed,” the most widely attended series of blood drives in California, beginning July ... blood over the past 4 years -- enough to have helped to save up to ...
Breaking Medicine News(10 mins):